The global peptide-based gastrointestinal disorders therapeutics market, valued at over USD 600 million in 2022, is projected to grow at a robust compound annual growth rate (CAGR) , driven by rising prevalence of gastrointestinal (GI) disorders and advancements in peptide drug developmen